Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Immune Thrombocytopenic Purpura Therapeutics Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Status and Forecast (2016-2027)
      • 1.3.2 Global Immune Thrombocytopenic Purpura Therapeutics Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Immune Thrombocytopenic Purpura Therapeutics Supply by Company

    • 2.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales Value by Company
    • 2.2 Immune Thrombocytopenic Purpura Therapeutics Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Immune Thrombocytopenic Purpura Therapeutics Market Status by Category

    • 3.1 Immune Thrombocytopenic Purpura Therapeutics Category Introduction
      • 3.1.1 Eltrombopag Olamine
      • 3.1.2 Fostamatinib Disodium
      • 3.1.3 GL-2045
      • 3.1.4 Avatrombopag
      • 3.1.5 BI-655064
      • 3.1.6 Others
    • 3.2 Global Immune Thrombocytopenic Purpura Therapeutics Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Immune Thrombocytopenic Purpura Therapeutics Market Status by End User/Segment

    • 4.1 Immune Thrombocytopenic Purpura Therapeutics Segment by End User/Segment
      • 4.1.1 Hospital
      • 4.1.2 Clinic
      • 4.1.3 Others
    • 4.2 Global Immune Thrombocytopenic Purpura Therapeutics Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Immune Thrombocytopenic Purpura Therapeutics Market Status by Region

    • 5.1 Global Immune Thrombocytopenic Purpura Therapeutics Market by Region
    • 5.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Status
    • 5.3 Europe Immune Thrombocytopenic Purpura Therapeutics Market Status
    • 5.4 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Status
    • 5.5 Central & South America Immune Thrombocytopenic Purpura Therapeutics Market Status
    • 5.6 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Status

    6 North America Immune Thrombocytopenic Purpura Therapeutics Market Status

    • 6.1 North America Immune Thrombocytopenic Purpura Therapeutics Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Immune Thrombocytopenic Purpura Therapeutics Market Status

    • 7.1 Europe Immune Thrombocytopenic Purpura Therapeutics Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Status

    • 8.1 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Immune Thrombocytopenic Purpura Therapeutics Market Status

    • 9.1 Central & South America Immune Thrombocytopenic Purpura Therapeutics Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Status

    • 10.1 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Immune Thrombocytopenic Purpura Therapeutics Market Forecast by Category and by End User/Segment

    • 12.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales Value Forecast (2022-2027)
    • 12.2 Global Immune Thrombocytopenic Purpura Therapeutics Forecast by Category
    • 12.3 Global Immune Thrombocytopenic Purpura Therapeutics Forecast by End User/Segment

    13 Global Immune Thrombocytopenic Purpura Therapeutics Market Forecast by Region/Country

    • 13.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Pfizer Inc.
      • 14.1.1 Company Information
      • 14.1.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.1.3 Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Novartis AG
      • 14.2.1 Company Information
      • 14.2.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.2.3 Novartis AG Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Momenta Pharmaceuticals, Inc.
      • 14.3.1 Company Information
      • 14.3.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.3.3 Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Merck & Co., Inc.
      • 14.4.1 Company Information
      • 14.4.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.4.3 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Jiangsu Hengrui Medicine Co., Ltd.
      • 14.5.1 Company Information
      • 14.5.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.5.3 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Intas Pharmaceuticals Ltd.
      • 14.6.1 Company Information
      • 14.6.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.6.3 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Immunomedics, Inc.
      • 14.7.1 Company Information
      • 14.7.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.7.3 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Hansa Medical AB
      • 14.8.1 Company Information
      • 14.8.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.8.3 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Eisai
      • 14.9.1 Company Information
      • 14.9.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.9.3 Eisai Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Bristol-Myers Squibb Company
      • 14.10.1 Company Information
      • 14.10.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
      • 14.10.3 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Boehringer Ingelheim GmbH
    • 14.12 Baxalta Incorporated
    • 14.13 Amgen Inc.

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Immune Thrombocytopenic Purpura Therapeutics market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Immune Thrombocytopenic Purpura Therapeutics market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Eltrombopag Olamine
      Fostamatinib Disodium
      GL-2045
      Avatrombopag
      BI-655064
      Others

      Segmented by End User/Segment
      Hospital
      Clinic
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Pfizer Inc.
      Novartis AG
      Momenta Pharmaceuticals, Inc.
      Merck & Co., Inc.
      Jiangsu Hengrui Medicine Co., Ltd.
      Intas Pharmaceuticals Ltd.
      Immunomedics, Inc.
      Hansa Medical AB
      Eisai
      Bristol-Myers Squibb Company
      Boehringer Ingelheim GmbH
      Baxalta Incorporated
      Amgen Inc.
      Buy now